📊 NIKA Key Takeaways
Is Nika Pharmaceuticals, Inc. (NIKA) a Good Investment?
NIKA Pharmaceuticals exhibits terminal financial distress with zero revenue, negative stockholders equity of -$297.6K indicating technical insolvency, and only $1.9K cash reserves against $318.6K liabilities. The company's unsustainable cash burn rate of -$79.7K annually combined with severe liquidity constraints (current ratio 0.07x) indicates imminent operational failure.
NIKA has no revenue, persistent operating losses, and severe liquidity stress with just $1.89K cash, a 0.07x current ratio, and negative equity. Operating cash outflow and liabilities far exceeding assets indicate reliance on external financing to continue as a going concern. Without a clear path to commercialization or improving fundamentals, downside risk remains high.
Why Buy Nika Pharmaceuticals, Inc. Stock? NIKA Key Strengths
- Company maintains minimal operational footprint reducing ongoing cash burn relative to active pharmaceutical operations
- Still reporting to SEC, indicating continuation through formal restructuring processes possible
- Low absolute operating loss (~$76K) limits cash burn magnitude
- No reported long‑term debt reduces interest obligations
- Losses flat YoY, suggesting some expense discipline
NIKA Stock Risks: Nika Pharmaceuticals, Inc. Investment Risks
- Negative stockholders equity of -$297.6K indicates technical insolvency and high bankruptcy risk
- Severe liquidity crisis with current ratio of 0.07x and only $1.9K cash against material liabilities
- Zero revenue generation with no demonstrated product commercialization or path to profitability
- Liabilities exceed total assets by 15x, creating structural insolvency
- Unsustainable cash burn of approximately -$79.7K annually with insufficient resources for continuation
- Going‑concern risk from negative equity and minimal cash
- High dilution risk due to need for external financing
- No revenue visibility or proof of commercialization
Key Metrics to Watch
- Monthly cash depletion rate and timeline to complete liquidity failure
- Any revenue generation or clinical trial advancement announcements
- Bankruptcy filing, debt restructuring, or capital raise announcements
- Quarterly operating cash burn and cash balance
- Current ratio and total short‑term liabilities
Nika Pharmaceuticals, Inc. (NIKA) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
NIKA Profit Margin, ROE & Profitability Analysis
NIKA vs Healthcare Sector: How Nika Pharmaceuticals, Inc. Compares
How Nika Pharmaceuticals, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Nika Pharmaceuticals, Inc. Stock Overvalued? NIKA Valuation Analysis 2026
Based on fundamental analysis, Nika Pharmaceuticals, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Nika Pharmaceuticals, Inc. Balance Sheet: NIKA Debt, Cash & Liquidity
NIKA Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Nika Pharmaceuticals, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $0.00 indicates the company is currently unprofitable.
NIKA Revenue Growth, EPS Growth & YoY Performance
NIKA Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2024 | $156 | -$27.8K | $0.00 |
| Q3 2023 | N/A | -$6.3K | N/A |
| Q2 2023 | N/A | -$6.3K | N/A |
| Q1 2023 | N/A | $6.3K | N/A |
| Q3 2022 | N/A | $2.7K | $0.00 |
| Q2 2022 | N/A | $3.0K | $0.00 |
| Q1 2022 | N/A | -$5.8K | $0.00 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Nika Pharmaceuticals, Inc. Dividends, Buybacks & Capital Allocation
NIKA SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Nika Pharmaceuticals, Inc. (CIK: 0001145604)
📋 Recent SEC Filings
❓ Frequently Asked Questions about NIKA
What is the AI rating for NIKA?
Nika Pharmaceuticals, Inc. (NIKA) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 95% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are NIKA's key strengths?
Claude: Company maintains minimal operational footprint reducing ongoing cash burn relative to active pharmaceutical operations. Still reporting to SEC, indicating continuation through formal restructuring processes possible. ChatGPT: Low absolute operating loss (~$76K) limits cash burn magnitude. No reported long‑term debt reduces interest obligations.
What are the risks of investing in NIKA?
Claude: Negative stockholders equity of -$297.6K indicates technical insolvency and high bankruptcy risk. Severe liquidity crisis with current ratio of 0.07x and only $1.9K cash against material liabilities. ChatGPT: Going‑concern risk from negative equity and minimal cash. High dilution risk due to need for external financing.
What is NIKA's revenue and growth?
Nika Pharmaceuticals, Inc. reported revenue of $0.0.
Does NIKA pay dividends?
Nika Pharmaceuticals, Inc. does not currently pay dividends.
Where can I find NIKA SEC filings?
Official SEC filings for Nika Pharmaceuticals, Inc. (CIK: 0001145604) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is NIKA's EPS?
Nika Pharmaceuticals, Inc. has a diluted EPS of $0.00.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is NIKA a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Nika Pharmaceuticals, Inc. has a STRONG SELL rating with 95% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is NIKA stock overvalued or undervalued?
Valuation metrics for NIKA: ROE of N/A (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy NIKA stock in 2026?
Our dual AI analysis gives Nika Pharmaceuticals, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is NIKA's free cash flow?
Nika Pharmaceuticals, Inc.'s operating cash flow is $-79.7K, with capital expenditures of N/A.
How does NIKA compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE N/A (avg: 15%), current ratio 0.07 (avg: 2).